Nuo Therapeutics Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Nuo Therapeutics has an operating margin of -180.0%, meaning the company retains $-180 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -520.6% the prior year.
Nuo Therapeutics's revenue surged 124.3% year-over-year to $1.4M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Nuo Therapeutics has a moderate D/E ratio of 1.32. This balance of debt and equity financing earns a leverage score of 62/100.
Nuo Therapeutics's current ratio of 1.45 indicates adequate short-term liquidity, earning a score of 38/100. The company can meet its near-term obligations, though with limited headroom.
While Nuo Therapeutics generated -$2.2M in operating cash flow, capex of $155K consumed most of it, leaving -$2.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Nuo Therapeutics passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Nuo Therapeutics generates $0.96 in operating cash flow (-$2.2M OCF vs -$2.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Nuo Therapeutics (AURX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Nuo Therapeutics generated $1.4M in revenue in fiscal year 2024. This represents an increase of 124.3% from the prior year.
Nuo Therapeutics's EBITDA was -$2.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 22.8% from the prior year.
Nuo Therapeutics generated -$2.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 24.8% from the prior year.
Nuo Therapeutics reported -$2.3M in net income in fiscal year 2024. This represents an increase of 26.7% from the prior year.
Nuo Therapeutics held $284K in cash against $0 in long-term debt as of fiscal year 2024.
Nuo Therapeutics had 47M shares outstanding in fiscal year 2024. This represents an increase of 5.8% from the prior year.
Nuo Therapeutics's gross margin was 77.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 1.5 percentage points from the prior year.
Nuo Therapeutics's operating margin was -180.0% in fiscal year 2024, reflecting core business profitability. This is up 340.6 percentage points from the prior year.
Nuo Therapeutics's net profit margin was -170.2% in fiscal year 2024, showing the share of revenue converted to profit. This is up 351.0 percentage points from the prior year.
Nuo Therapeutics invested $155K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 2039.2% from the prior year.
AURX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M+47.4% | $700K+44.6% | $484K+22.7% | $395K+8.3% | $365K+55.5% | $235K+19.1% | $197K-15.2% | $232K |
| Cost of Revenue | $407K+155.2% | $159K+31.7% | $121K+40.1% | $86K+32.3% | $65K+29.1% | $51K+22.3% | $41K-23.1% | $54K |
| Gross Profit | $625K+15.6% | $541K+48.8% | $363K+17.8% | $308K+3.0% | $299K+62.8% | $184K+18.2% | $156K-12.8% | $178K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $1.2M-2.3% | $1.2M+7.6% | $1.1M+18.2% | $938K+11.4% | $841K-5.8% | $893K+10.6% | $808K-16.6% | $968K |
| Operating Income | -$540K+17.2% | -$652K+12.5% | -$745K-18.4% | -$629K-16.1% | -$542K+23.6% | -$709K-8.8% | -$652K+17.4% | -$790K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$538K+17.2% | -$650K+12.9% | -$746K-50.2% | -$497K+8.0% | -$540K+23.8% | -$709K-8.5% | -$653K+17.4% | -$791K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AURX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.9M+41.8% | $1.4M+18.6% | $1.1M-3.6% | $1.2M-16.3% | $1.4M+14.3% | $1.2M-33.8% | $1.9M+17.4% | $1.6M |
| Current Assets | $1.5M+71.4% | $853K+41.9% | $602K-28.5% | $842K-28.4% | $1.2M+19.7% | $981K-37.2% | $1.6M+24.2% | $1.3M |
| Cash & Equivalents | $515K+62.7% | $316K+468.4% | $56K-80.4% | $284K-40.0% | $473K+29.2% | $366K-60.6% | $929K+59.4% | $583K |
| Inventory | $202K+21.6% | $166K+67.2% | $99K-34.1% | $150K-30.6% | $217K+2.6% | $211K+0.9% | $210K0.0% | $210K |
| Accounts Receivable | $652K+103.5% | $320K+15.9% | $277K+11.4% | $248K-18.6% | $305K+32.7% | $230K-8.4% | $251K+7.7% | $233K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.3M+7.5% | $2.2M+60.6% | $1.4M+101.2% | $676K-17.8% | $822K-9.6% | $909K+8.4% | $839K-3.9% | $873K |
| Current Liabilities | $1.3M+25.8% | $999K-22.0% | $1.3M+121.4% | $578K-16.2% | $690K-9.3% | $761K+12.9% | $675K-1.6% | $685K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$420K+49.1% | -$825K-287.0% | -$213K-141.5% | $514K-14.2% | $599K+79.5% | $333K-67.9% | $1.0M+43.0% | $727K |
| Retained Earnings | -$34.2M-1.6% | -$33.7M-2.0% | -$33.0M-2.3% | -$32.3M-3.4% | -$31.2M-1.8% | -$30.6M-2.4% | -$29.9M-2.2% | -$29.3M |
AURX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$707K-369.3% | $262K+14276.2% | $2K+100.4% | -$491K+29.0% | -$691K-22.9% | -$562K+16.2% | -$671K+15.5% | -$795K |
| Capital Expenditures | $0-100.0% | $2K-99.3% | $230K | $0-100.0% | $4K | $0 | $0-100.0% | $2K |
| Free Cash Flow | -$707K-371.0% | $261K+214.3% | -$228K+53.5% | -$491K+29.4% | -$695K-23.6% | -$562K+16.2% | -$671K+15.7% | -$797K |
| Investing Cash Flow | $0+100.0% | -$2K+99.3% | -$230K | $0+100.0% | -$4K | $0 | $0+100.0% | -$2K |
| Financing Cash Flow | $905K | $0 | $0-100.0% | $90K-88.7% | $802K | $0-100.0% | $963K-7.0% | $1.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AURX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.6%-16.6pp | 77.2%+2.2pp | 75.0%-3.1pp | 78.1%-4.0pp | 82.1%+3.7pp | 78.4%-0.6pp | 79.0%+2.2pp | 76.8% |
| Operating Margin | -52.3%+40.8pp | -93.1%+60.7pp | -153.8%+5.5pp | -159.3%-10.8pp | -148.6%+153.8pp | -302.3%+28.6pp | -331.0%+9.0pp | -340.0% |
| Net Margin | -52.1%+40.7pp | -92.8%+61.3pp | -154.0%-28.3pp | -125.8%+22.3pp | -148.1%+154.1pp | -302.2%+29.4pp | -331.5%+8.9pp | -340.4% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -27.9%+19.9pp | -47.8%+17.3pp | -65.1%-23.3pp | -41.8%-3.7pp | -38.0%+19.0pp | -57.0%-22.3pp | -34.8%+14.6pp | -49.4% |
| Current Ratio | 1.16+0.3 | 0.85+0.4 | 0.47-1.0 | 1.45-0.2 | 1.70+0.4 | 1.29-1.0 | 2.32+0.5 | 1.84 |
| Debt-to-Equity | -5.59-2.9 | -2.65+3.7 | -6.38-7.7 | 1.32-0.1 | 1.37-1.4 | 2.73+1.9 | 0.81-0.4 | 1.20 |
| FCF Margin | -68.5%-105.7pp | 37.2%+84.3pp | -47.1%+77.1pp | -124.2%+66.4pp | -190.6%+49.2pp | -239.8%+101.0pp | -340.8%+2.3pp | -343.1% |
Similar Companies
Frequently Asked Questions
What is Nuo Therapeutics's annual revenue?
Nuo Therapeutics (AURX) reported $1.4M in total revenue for fiscal year 2024. This represents a 124.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nuo Therapeutics's revenue growing?
Nuo Therapeutics (AURX) revenue grew by 124.3% year-over-year, from $609K to $1.4M in fiscal year 2024.
Is Nuo Therapeutics profitable?
No, Nuo Therapeutics (AURX) reported a net income of -$2.3M in fiscal year 2024, with a net profit margin of -170.2%.
What is Nuo Therapeutics's EBITDA?
Nuo Therapeutics (AURX) had EBITDA of -$2.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nuo Therapeutics's gross margin?
Nuo Therapeutics (AURX) had a gross margin of 77.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Nuo Therapeutics's operating margin?
Nuo Therapeutics (AURX) had an operating margin of -180.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Nuo Therapeutics's net profit margin?
Nuo Therapeutics (AURX) had a net profit margin of -170.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Nuo Therapeutics's free cash flow?
Nuo Therapeutics (AURX) generated -$2.4M in free cash flow during fiscal year 2024. This represents a 24.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nuo Therapeutics's operating cash flow?
Nuo Therapeutics (AURX) generated -$2.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Nuo Therapeutics's total assets?
Nuo Therapeutics (AURX) had $1.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Nuo Therapeutics's capital expenditures?
Nuo Therapeutics (AURX) invested $155K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How many shares does Nuo Therapeutics have outstanding?
Nuo Therapeutics (AURX) had 47M shares outstanding as of fiscal year 2024.
What is Nuo Therapeutics's current ratio?
Nuo Therapeutics (AURX) had a current ratio of 1.45 as of fiscal year 2024, which is considered adequate.
What is Nuo Therapeutics's debt-to-equity ratio?
Nuo Therapeutics (AURX) had a debt-to-equity ratio of 1.32 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nuo Therapeutics's return on assets (ROA)?
Nuo Therapeutics (AURX) had a return on assets of -195.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Nuo Therapeutics's cash runway?
Based on fiscal year 2024 data, Nuo Therapeutics (AURX) had $284K in cash against an annual operating cash burn of $2.2M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Nuo Therapeutics's Piotroski F-Score?
Nuo Therapeutics (AURX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nuo Therapeutics's earnings high quality?
Nuo Therapeutics (AURX) has an earnings quality ratio of 0.96x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Nuo Therapeutics?
Nuo Therapeutics (AURX) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.